Losartan Potassium Tablet, Film Coated
Product Images NDC 60760-786

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 60760-786). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Loa (Losartan 60760 786 30)

Label for Losartan Potassium 50 mg film-coated tablets, quantity of 30. The label shows the drug name, strength, and quantity along with placeholder information for lot number and expiration date. Manufactured by Hetero Labs Limited, India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. Contains a barcode and storage instructions at controlled room temperature (15°-30°C).*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Atenolol and Losartan potassium. The graph shows trends with Atenolol indicated by a dotted line and Losartan potassium by a solid line, including an annotation of adjusted risk reduction of 13% with statistical significance (p=0.021).*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over 66 months between two medications: Atenolol and Losartan potassium. The x-axis represents study months, and the y-axis shows the percentage of affected patients. The graph includes a note of adjusted risk reduction of 25% favoring Losartan potassium, with a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' showing comparative data between Losartan Potassium and Atenolol. It includes primary composite event rates and stroke event rates (fatal/non-fatal) across demographics such as age, gender, race, isolated systolic hypertension (ISH), diabetes status, and history of cardiovascular disease (CVD). Hazard ratios with 95% confidence intervals are plotted to indicate comparative risk between the two treatments.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph showing the percentage of patients with events over time up to 48 months, comparing Losartan potassium and placebo. The graph indicates risk reduction with Losartan potassium at 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium, showing its molecular components including a chlorinated biphenyl group, a tetrazole ring, and other characteristic functional groups relevant to the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.